MedTrace Logo

An Experimental Study of Belzutifan Impact on Catecholamine Metabolism

NCT07680205 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-07-02

No results posted yet for this study

Summary

To investigate the impact of a medication called Belzutifan on the production and subsequent metabolism of adrenaline and noradrenaline collectively termed 'catecholamines'. The study aims to identify changes in the production and metabolism of catecholamines by measuring the substance which starts the chain of catecholamine metabolism called tyrosine in patients before, during and after 5 days of taking Belzutifan 120mg daily.

Conditions

  • Pheochromocytoma and Paraganglioma (PPGL)
  • Pheochromocytoma Malignant
  • Pheochromocytoma, Metastatic
  • Pheochromocytoma/Paraganglioma
  • Pheochromocytoma

Interventions

DRUG

Belzutifan

Belzutifan 120mg daily for 5 days

Sponsors & Collaborators

Principal Investigators

  • Ruth T Casey, MD PhD · Cambridge University Hospital and University of Cambridge

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-27
Primary Completion
2027-04-30
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07680205 on ClinicalTrials.gov